Skip to content

Study · Not a test of the peptide alone · 2017

4 results

Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.

Abdul-Ghani M, Migahid O, Megahed A, DeFronzo RA, Zirie M, Jayyousi A

The Journal of clinical endocrinology and metabolism1 Jul 2017Cited by 12 (Europe PMC)

PMID28324038 (opens in a new tab)DOI10.1210/jc.2016-3423 (opens in a new tab)PepBankPUB-28324038
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In poorly controlled type 2 diabetes, exenatide plus pioglitazone lowered HbA1c more than basal/bolus insulin at 6 months.

    In plain wordsIn poorly controlled type 2 diabetes, exenatide plus pioglitazone lowered HbA1c more than basal/bolus insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c at 6 months
    Study

    n = 101

    Comparator
    Basal plus prandial insulin
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c at 6 months
    6.7%
    Exenatide plus pioglitazone group
    HbA1c change from baseline at 6 months
    −4.8%
    Exenatide plus pioglitazone group
    HbA1c at 6 months
    7.4%
    Basal plus prandial insulin group
    HbA1c change from baseline at 6 months
    −3.8%
    Basal plus prandial insulin group

    Source sentences

    Summary
    At 6 months, combination therapy caused a robust decrease in HbA1c to 6.7% ± 0.1% (∆ = -4.8%) compared with 7.4% ± 0.1% (∆ = -3.8%) in subjects receiving insulin therapy.
    2 context sentences
    Summary · context
    Participants (n = 101) in the Qatar Study with very poor glycemic control (HbA1c >10%) and a long duration of diabetes (10.9 years) receiving maximum/near-maximum doses of sulfonylurea plus metformin
    Summary · context
    were randomly assigned to receive pioglitazone plus weekly exenatide (combination therapy), or basal plus prandial insulin (insulin therapy), to maintain HbA1c <7.0%.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In poorly controlled type 2 diabetes, weight gain was lower with exenatide plus pioglitazone than basal/bolus insulin.

    In plain wordsIn poorly controlled type 2 diabetes, weight gain was lower with exenatide plus pioglitazone than basal/bolus insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight gain
    Study

    n = 101

    Comparator
    Basal plus prandial insulin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Subjects in the insulin therapy group experienced significantly greater weight gain and a 2.5-fold higher rate of hypoglycemia compared with patients receiving combination therapy.
    2 context sentences
    Summary · context
    Participants (n = 101) in the Qatar Study with very poor glycemic control (HbA1c >10%) and a long duration of diabetes (10.9 years) receiving maximum/near-maximum doses of sulfonylurea plus metformin
    Summary · context
    were randomly assigned to receive pioglitazone plus weekly exenatide (combination therapy), or basal plus prandial insulin (insulin therapy), to maintain HbA1c <7.0%.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome

    In poorly controlled type 2 diabetes, hypoglycemia was less frequent with exenatide plus pioglitazone than basal/bolus insulin.

    In plain wordsIn poorly controlled type 2 diabetes, low blood sugar was less frequent with exenatide plus pioglitazone than basal/bolus insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHypoglycemia rate
    Study

    n = 101

    Comparator
    Basal plus prandial insulin
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Hypoglycemia rate ratio, insulin therapy versus exenatide plus pioglitazone
    2.5 fold
    Insulin therapy group versus combination therapy group

    Source sentences

    Summary
    Subjects in the insulin therapy group experienced significantly greater weight gain and a 2.5-fold higher rate of hypoglycemia compared with patients receiving combination therapy.
    2 context sentences
    Summary · context
    Participants (n = 101) in the Qatar Study with very poor glycemic control (HbA1c >10%) and a long duration of diabetes (10.9 years) receiving maximum/near-maximum doses of sulfonylurea plus metformin
    Summary · context
    were randomly assigned to receive pioglitazone plus weekly exenatide (combination therapy), or basal plus prandial insulin (insulin therapy), to maintain HbA1c <7.0%.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In poorly controlled type 2 diabetes, exenatide plus pioglitazone lowered HbA1c independently of sex, ethnicity or body mass index.

    In plain wordsIn poorly controlled type 2 diabetes, exenatide plus pioglitazone lowered HbA1c independently of sex, ethnicity or body mass index.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c response across demographic groups
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Combination therapy was effective in lowering the HbA1c independent of sex, ethnicity, or body mass index.
    2 context sentences
    Summary · context
    Participants (n = 101) in the Qatar Study with very poor glycemic control (HbA1c >10%) and a long duration of diabetes (10.9 years) receiving maximum/near-maximum doses of sulfonylurea plus metformin
    Summary · context
    were randomly assigned to receive pioglitazone plus weekly exenatide (combination therapy), or basal plus prandial insulin (insulin therapy), to maintain HbA1c <7.0%.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.